Improving diagnosis and treatment of head and neck cancer through epigenetic profiling
Official title: Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer
Run by European Institute of Oncology · NCT06706973 · Data updated 2026-11-12
This study is testing if looking at specific changes in genes can help doctors better diagnose and treat head and neck cancer in adults who haven't had treatment yet.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | European Institute of Oncology Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Milan, MI) |
| Status | Recruiting |
| Started | March 6, 2024 |
| Main results expected | April 4, 2030 |
| Study ends | April 4, 2030 |
| Registry record updated | November 27, 2024 |
| Trial ID | NCT06706973 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with treatment-naïve primary squamous cell carcinoma of the head and neck.
✕Probably not a fit
Patients who have previously undergone radiotherapy, chemotherapy, or immunotherapy for head and neck cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the role of epigenetic marks in head and neck cancer (HNC) to identify potential therapeutic targets. It focuses on distinguishing between HPV-positive and HPV-negative HNC by analyzing unique histone modifications. The research aims to understand how these epigenetic changes contribute to tumorigenesis in HNC, which could lead to more effective treatment strategies. Participants will include adults diagnosed with primary squamous cell carcinoma of the oral cavity, larynx, oropharynx, who have not received prior treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and targeted therapies for patients with head and neck cancer.
How similar studies have gone: Other studies have shown promise in targeting epigenetic modifications in various cancers, suggesting potential success for this approach in head and neck cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics Exclusion Criteria: * Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent
Where it's running
-
European Institute of oncology
Milan, Mi, Italy Recruiting
Study contacts
- Principal investigator: Susanna Chiocca — Istituto Europeo di Oncologia
- Study coordinator: Susanna Chiocca, Doctor
- Email: susanna.chiocca@ieo.it
- Phone: 00390257488835
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.